Go back to the Europarl portal

Choisissez la langue de votre document :

  • bg - български
  • es - español
  • cs - čeština
  • da - dansk
  • de - Deutsch
  • et - eesti keel
  • el - ελληνικά
  • en - English (Selected)
  • fr - français
  • ga - Gaeilge
  • hr - hrvatski
  • it - italiano
  • lv - latviešu valoda
  • lt - lietuvių kalba
  • hu - magyar
  • mt - Malti
  • nl - Nederlands
  • pl - polski
  • pt - português
  • ro - română
  • sk - slovenčina
  • sl - slovenščina
  • fi - suomi
  • sv - svenska
Parliamentary questions
PDF 101kWORD 16k
2 September 2016
E-006648-16
Question for written answer E-006648-16
to the Commission
Rule 130
DAME Glenis Willmott (S&D) , Judith Sargentini (Verts/ALE) , Beatriz Becerra Basterrechea (ALDE)

 Subject:  Antimicrobial resistance
 Answer in writing 

Drug-resistant infections are a looming global challenge. The O’Neill Report, published in May 2016, estimates that by 2050, 10 million lives a year and a cumulative USD 100 trillion of economic output are at risk, owing to a rise in drug-resistant infections. To tackle this growing issue, three key interventions have been identified by the Global Action Plan and by the World Health Organisation (WHO) secretariat in their development and stewardship report: improving stewardship and appropriate use of existing antibiotics; ensuring that innovation is driven by public health needs for future medical tools to diagnose, treat and cure infection; and affordable access to existing and new medical tools.

Does the Commission support the creation of a global antimicrobial resistance (AMR) development and stewardship framework under the auspices of the WHO?

Furthermore, the Innovative Medicines Initiative (IMI) is investing a significant amount of public money in research and development projects on AMR (e.g. more than USD 6 million in the DRIVE-AB programme). When will the first results of the DRIVE-AB programme be published?

How will the IMI ensure that the dual public health objective on access and stewardship will be addressed in its other development programmes — in particular in the COMBACTE and TRANSLOCATION programmes?

Legal notice